Urology
Volume 64, Issue 5 , Pages 855-861 , November 2004

Combining external beam radiotherapy with prostate brachytherapy: Issues and rationale

  • Clarissa Febles

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania USA
    • ,
  • Richard K. Valicenti

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania USA
    • Corresponding Author InformationReprint requests: Richard K. Valicenti, M.D., Department of Radiation Oncology, Thomas Jefferson University Hospital, Bodine Center for Cancer Treatment, 111 South 11th Street, Philadelphia, PA 19107

Received 19 February 2004 ,Accepted 21 June 2004.

References 

  1. D’Amico AV , Whittington R , Malkowicz SB , et al.   Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer . JAMA . 1998;280:969–974
  2. Zelefsky MJ , Wallner KE , Ling CC , et al.   Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer . J Clin Oncol . 1999;17:517–522
  3. Blasko JC , Wallner K , Grimm PD , et al.   Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma . J Urol . 1995;154:1096–1099
  4. Kuban DA , El-Mahdi AM , Schellhammer PF . I-125 interstitial implantation for prostate cancer (what have we learned 10 years later?) . Cancer . 1989;63:2415–2420
  5. Kwok Y , DiBiase SJ , Amin PP , et al.   Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy . Int J Radiat Oncol Biol Phys . 2002;53:588–594
  6. Hanks GE , Hanlon AL , Pinover WH , et al.   Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy . Cancer J Sci Am . 1999;5:152–158
  7. Hanks GE , Martz KL , Diamond JJ . The effect of dose on local control of prostate cancer . Int J Radiat Oncol Biol Phys . 1988;15:1299–1305
  8. Pollack A , Smith LG , von Eschenbach AC . External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era . Int J Radiat Oncol Biol Phys . 2000;48:507–512
  9. Zelefsky MJ , Leibel SA , Gaudin PB , et al.   Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer . Int J Radiat Oncol Biol Phys . 1998;41:491–500
  10. Valicenti R , Lu J , Pilepich M , et al.   Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trial . J Clin Oncol . 2000;18:2740–2746
  11. Stock RG , Stone NN , Tabert A , et al.   A dose-response study for iodine-125 prostate implants . Int J Radiat Oncol Biol Phys . 1998;41:101–108
  12. Chen A , Roach M , Diaz A , et al.   Using pre-treatment PSA and Gleason score to predict for extra capsular extension among patients with clinically staged organ confined prostate cancer . Int J Radiat Oncol Biol Phys . 1995;32(suppl 1):232–233
  13. Partin AW , Mangold LA , Lamm DM , et al.   Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium . Urology . 2001;58:843–848
  14. Roach M . The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer . J Urol . 1993;150:1923–1924
  15. Davis BJ , Pisansky TM , Wilson TM , et al.   The radial distance of extraprostatic extension of prostate carcinoma (implications for prostate brachytherapy) . Cancer . 1999;85:2630–2637
  16. Roach M , DeSilvio M , Lawton C , et al.  Radiation Therapy Oncology Group 9413   Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression . J Clin Oncol . 2003;21:1904–1911
  17. Waterman FM , Yue N , Corn BW , et al.   Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry (an analysis based on serial CT acquisition) . Int J Radiat Oncol Biol Phys . 1998;41:1069–1077
  18. Nag S , Bice W , DeWyngaert K , et al.   The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis . Int J Radiat Oncol Biol Phys . 2000;46:221–230
  19. Nag S . Brachytherapy for prostate cancer (summary of American Brachytherapy Society recommendations) . Semin Urol Oncol . 2000;18:133–136
  20. Dattoli M , Wallner K , Sorace R , et al.   103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma . Int J Radiat Oncol Biol Phys . 1996;35:875–879
  21. Critz FA , Levinson AK , Williams WH , et al.   Simultaneous radiotherapy for prostate cancer (125I prostate implant followed by external-beam radiation) . Cancer J Sci Am . 1998;4:359–363
  22. Ragde H , Korb L , Elgamal A , et al.   Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up . Cancer . 2000;89:135–141
  23. Ragde H , Elgamal AA , Snow PB , et al.   Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma . Cancer . 1998;83:989–1001
  24. Critz FA , Levinson K , Williams WH , et al.   Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer . Urology . 1997;49:668–672
  25. Grado GL , Larson TR , Balch CS , et al.   Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance . Int J Radiat Oncol Biol Phys . 1998;42:289–298
  26. Singh A , Zelefsky MJ , Raben A , et al.   Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer . Int J Radiat Oncol Biol Phys . 2000;90:275–280
  27. Merrick GS , Butler WM , Lief JH , et al.   Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation . Brachytherapy . 2002;8:322–327
  28. Wallner KE , Roy J , Zelefsky M , et al.   Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 125I prostate brachytherapy . Int J Radiat Oncol Biol Phys . 1995;32:465–471
  29. Critz FA , Tarlton RS , Holladay DA . Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer (I-125 implant followed by external beam radiation) . Cancer . 1995;75:2383–2391
  30. Mate TP , Gottesman JE , Hatton J , et al.   High dose rate after loading iridium 192 prostate brachytherapy (feasibility report) . Int J Radiat Oncol Biol Phys . 1998;41:525–533
  31. Kestin LL , Martinez AA , Stromberg JS , et al.   Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer . J Clin Oncol . 2000;18:2869–2880
  32. Pilepich MV , Winter K , John MJ , et al.   Phase III Radiation Therapy Oncology Group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate . Int J Radiat Oncol Biol Phys . 2001;50:1243–1252
  33. Pilepich MV , Caplan RW , Byhardt RW , et al.   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy (report of Radiation Therapy Oncology Group protocol 85–31) . J Clin Oncol . 1997;15:1013–1021
  34. Bolla M , Gonzalez D , Warde P , et al.   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin . N Engl J Med . 1997;337:295–300
  35. Stone NN , Stock RG , Unger P . Effects of neoadjuvant hormonal therapy on prostate biopsy results after 125 I and 103 Pd seed implantation . Mol Urol . 2000;4:163–168
  36. Sylvester J , Blasko JC , Grimm PD , et al.   Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer (a matched subset analysis) . Mol Urol . 2000;4:155–159

PII: S0090-4295(04)00821-0

doi: 10.1016/j.urology.2004.06.053

Urology
Volume 64, Issue 5 , Pages 855-861 , November 2004

Article Tools